Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03)

Phase 2CompletedNCT03052062

Valbiotis20 enrolled

Overview

The objectives of this clinical study are to determine the tolerance of dietary supplement Lipidrive through the evaluation of several parameters : * Various blood biological parameters * Urinary parameters * Hemodynamic indicators * Cardiac function * Anthropometric variables

Primary objectives of this study : Evaluate the effects of two doses of the product on: * Various blood biological parameters for tolerance (preprandial): blood glucose, insulin, HOMA-IR, glycated hemoglobin, fructosamine, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, oxidized LDL, us-CRP, creatinine, ASAT, ALAT, gGT, alkaline phosphatase, bilirubin, urea. * Urinary parameters: urea, creatinine. * Hemodynamic indicators: heart rate and blood pressure. * Cardiac function: ECG. * Anthropometric variables: weight, waist, hips, waist/hip ratio, body composition using bioelectric impendence analysis. Secondary objectives of this study: Evaluate the effects of the highest dose on: \- Adiponectin, leptin, TNF-α, and the evolution kinetics of blood glucose and blood insulin levels following a standard breakfast, with or without the acute administration of the Lipidrive dietary supplement. Two questionnaires (one on eating habits over 3 days and another on physical and sports activities) will be completed at various times (cf. below). A "satisfaction" questionnaire will also be completed at the end of the study. A serum bank will be created (ghrelin, resistin, GIP, GLP-1, IL-6, IL-1 beta, CCK), and stools will be collected at V2 and V5 for subsequent microbiota analysis (aliquoting performed by the AME2P laboratory, which will send the samples to BIOFORTIS Nantes at the end of the trial).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Obese

Interventions

LipidriveDIETARY_SUPPLEMENT

LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day

Eligibility

Sex: MALEMin age: 45 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male * Aged 45 to 65 years (inclusive) * BMI between 30 kg/m² (inclusive) and 40 kg/m² (non-inclusive) and/or a waist/hips ratio \> 0.9 * Non-smoker or smokes maximum 10 cigarettes per day * Stable weight for at least 3 months before the start of the study * Regular physical activity for 3 months before the start of the study, subject agreeing to maintain this level of activity over the course of the study * Stable eating habits for 3 months before the start of the study, subject agreeing to maintain these eating habits over the course of the study * Willing and able to comply with the protocol, subject agreeing to give their informed written consent * Registered with a social security scheme * Subject agreeing to be registered in the national directory of volunteers participating in biomedical research Following the biological screening conducted during the inclusion visit, run-in subjects will be included at the following visit according to the following criteria: * FBC with no clinically significant anomalies according to the investigator * ASAT ≤ 1.55 μkat/L or ≤ 92 U/L * ALAT ≤ 1.7 μkat/L or ≤ 101 U/L * gGT ≤ 2.55 μkat/L or ≤ 152 U/L * 45 ≤ Creatinine ≤ 104 μmol/L (± 10%) * Total bilirubin \< 17.1 μmol/L (± 10%) * 1.7 mmol/L ≤ Urea ≤ 8.3 mmol/L (± 10%) * us-CRP ≤ 5 mg/L (± 10%). Exclusion Criteria: * Confirmed or suspected food allergy to the test product (describe) * Subject with chronic condition or specific circumstances that the investigator considers incompatible with participation in the study * Subject taking anti-diabetic treatment * Subject taking lipo-regulating (fibrates, statins, nicotinic acid) or anti-dyslipidemia drugs * Subject consuming dietary supplements (V0 could be conducted at least 1 month after completely stopping the supplements) * Subject consuming grapefruit or orange juice (enzyme inhibitor) * Subject consuming food products supplemented with phytosterols, beta glucans, konjac, and/or cinnamon (V0 could be conducted at least 3 months after completely stopping the supplements) (list to be drawn up at the time of the study) * Unstable blood pressure equal to or over 160/95 * Subject undergoing treatment that, according to the investigator, could interfere with the evaluation of the study criteria * Subject who has been on a low-calorie diet in the 3 months prior to the study and/or intends to go on a diet during the study * Subject with serious history of anorexia nervosa, bulimia or other eating disorders * Vegetarian or vegan * Extreme eating habits * Subject participating in another clinical study or in an exclusion period following a previous clinical study * Subject who has received over 4500 euros in compensation since the start of the calendar year (sum can vary according to regulations) * Subject with a linguistic or physical incapacity to provide written informed consent * Refusal to provide written consent * Subject deprived of liberty by administrative or judicial order, under trusteeship or guardianship * Subject who cannot be contacted by telephone in case of emergency

Locations (1)

Centre d'Investigation Clinique

Clermont-Ferrand, France

Outcomes

Primary Outcomes

Changes in fasting blood glucose

Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L

Time frame: 12 weeks

Changes in fasting blood glucose

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mmol/L

Time frame: 26 weeks

Changes in fasting insulinemia

Defined as the difference V3 (12 weeks) - V2 (baseline)) in mUI/L

Time frame: 12 weeks

Changes in fasting insulinemia

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mUI/L

Time frame: 26 weeks

Changes in fasting HOMA-IR

Defined as the difference V3 (12 weeks) - V2 (baseline)

Time frame: 12 weeks

Changes in fasting HOMA-IR

Defined as the difference V5 (26 weeks) - V4 (14 weeks)

Time frame: 26 weeks

Changes in glycated hemoglobin

Defined as the difference V3 (12 weeks) - V2 (baseline) in %

Time frame: 12 weeks

Changes in glycated hemoglobin

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in %

Time frame: 26 weeks

Changes in fasting fructosamin

Defined as the difference V3 (12 weeks) - V2 (baseline) in µmol/L

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Changes in fasting fructosamin

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in µmol/L

Time frame: 26 weeks

Changes in fasting total cholesterol

Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L

Time frame: 12 weeks

Changes in fasting total cholesterol

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mmol/L

Time frame: 26 weeks

Changes in fasting HDL cholesterol

Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L

Time frame: 12 weeks

Changes in fasting HDL cholesterol

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mmol/L

Time frame: 26 weeks

Changes in fasting LDL cholesterol

Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L

Time frame: 12 weeks

Changes in fasting LDL cholesterol

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mmol/L

Time frame: 26 weeks

Changes in fasting triglycerides

Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L

Time frame: 12 weeks

Changes in fasting triglycerides

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mmol/L

Time frame: 26 weeks

Changes in oxidized LDL

Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L

Time frame: 12 weeks

Changes in oxidized LDL

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mmol/L

Time frame: 26 weeks

Changes in us-CRP

Defined as the difference V3 (12 weeks) - V2 (baseline) in mg/L

Time frame: 12 weeks

Changes in us-CRP

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mmol/L

Time frame: 26 weeks

Changes in blood creatinine

Defined as the difference V3 (12 weeks) - V2 (baseline) in mg/dL

Time frame: 12 weeks

Changes in blood creatinine

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mg/dL

Time frame: 26 weeks

Changes in fasting blood levels of ASAT (Aspartate aminotransferase) and ALAT (Alanine aminotransferase)

Defined as the difference V3 (12 weeks) - V2 (baseline) in UI/L

Time frame: 12 weeks

Changes in fasting blood levels of ASAT (Aspartate aminotransferase) and ALAT (Alanine aminotransferase)

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in UI/L

Time frame: 26 weeks

Changes in fasting blood levels of GGT (Gamma glutamyltransferase)

Defined as the difference V3 (12 weeks) - V2 (baseline) in UI/L

Time frame: 12 weeks

Changes in fasting blood levels of GGT (Gamma glutamyltransferase)

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in UI/L

Time frame: 26 weeks

Changes in fasting alkaline phosphatase

Defined as the difference V3 (12 weeks) - V2 (baseline) in UI/L

Time frame: 12 weeks

Changes in fasting alkaline phosphatase

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in UI/L

Time frame: 26 weeks

Changes in fasting blood bilirubin

Defined as the difference V3 (12 weeks) - V2 (baseline) in µmol/L

Time frame: 12 weeks

Changes in fasting blood bilirubin

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in µmol/L

Time frame: 26 weeks

Changes in fasting blood urea

Defined as the difference V3 (12 weeks) - V2 (baseline) in mg/dL

Time frame: 12 weeks

Changes in fasting blood urea

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mg/dL

Time frame: 26 weeks

Changes in heart rate

Defined as the difference V3 (12 weeks) - V2 (baseline) in bpm

Time frame: 12 weeks

Changes in heart rate

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in bpm

Time frame: 26 weeks

Changes in SBP (systolic blood pressure) and DBP (diastolic blood pressure)

Defined as the difference V3 (12 weeks) - V2 (baseline) in mmHg (mean of the two measures for each parameter at each visit)

Time frame: 12 weeks

Changes in SBP (systolic blood pressure) and DBP (diastolic blood pressure)

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in mmHg (mean of the two measures for each parameter at each visit)

Time frame: 26 weeks

Changes in cardiac function (electrocardiogram, ECG)

Defined as the difference V3 (12 weeks) - V2 (baseline)

Time frame: 12 weeks

Changes in cardiac function (electrocardiogram, ECG)

Defined as the difference V5 (26 weeks) - V4 (14 weeks)

Time frame: 26 weeks

Changes in body weight

Defined as the difference V3 (12 weeks) - V2 (baseline) in kg

Time frame: 12 weeks

Changes in body weight

Defined as the difference V5 (26 weeks) - V4 (14 weeks) in kg

Time frame: 26 weeks

Changes in WC (waist circumference)

Defined as the difference V3 (12 weeks) - V2 (baseline)

Time frame: 12 weeks

Changes in WC (waist circumference)

Defined as the difference V5 (26 weeks) - V4 (14 weeks)

Time frame: 26 weeks

Changes in HC (hip circumference)

Defined as the difference V3 (12 weeks) - V2 (baseline)

Time frame: 12 weeks

Changes in HC (hip circumference)

Defined as the difference V5 (26 weeks) - V4 (14 weeks)

Time frame: 26 weeks

Changes in WHR (waist to hip ratio)

Defined as the difference V3 (12 weeks) - V2 (baseline)

Time frame: 12 weeks

Changes in WHR (waist to hip ratio)

Defined as the difference V5 (26 weeks) - V4 (14 weeks)

Time frame: 26 weeks

Changes in body composition

Defined as the difference V3 (12 weeks) - V2 (baseline), using bioelectric impendence analysis

Time frame: 12 weeks

Changes in body composition

Defined as the difference V5 (26 weeks) - V4 (14 weeks), using bioelectric impendence analysis

Time frame: 26 weeks

Secondary Outcomes

Changes in fasting blood adiponectin

Defined as the difference V5 (26 weeks) - V4 (14 weeks)

Time frame: 26 weeks

Changes in fasting blood leptin

Defined as the difference V5 (26 weeks) - V4 (14 weeks)

Time frame: 26 weeks

Changes in the evolution of glycemia during an oral glucid tolerance test

Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mmol/L) of glycemia at 15, 30, 45, 60, 90 and 120 minutes between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120

Time frame: 26 weeks

Changes in the incremental area under the curve (glycemia response) during an oral glucid tolerance test

Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mmol/L) of incremental Area Under the Curve (iAUC) of glycemia between T0 and T120 minutes following a standard breakfast (iAUC0-120min) and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120

Time frame: 26 weeks

Changes in the glycemia Cmax during an oral glucid tolerance test

Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUIl/L) of glycemia Cmax between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120

Time frame: 26 weeks

Changes in the glycemia Δpeak during an oral glucid tolerance test

Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mmol/L) of Δpeak (difference from the baseline at Cmax), between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120

Time frame: 26 weeks

Changes in the evolution of insulinemia during an oral glucid tolerance test

Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUI/L) of insulinemia at 15, 30, 45, 60, 90 and 120 minutes between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120

Time frame: 26 weeks

Changes in the incremental area under the curve (insulinemia response) during an oral glucid tolerance test

Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUI/L) of incremental Area Under the Curve (iAUC) of insulinemia between T0 and T120 minutes following a standard breakfast (iAUC0-120min) and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120

Time frame: 26 weeks

Changes in the insulinemia Cmax during an oral glucid tolerance test

Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUIl/L) of insulinemia Cmax between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120

Time frame: 26 weeks

Changes in the insulinemia Δpeak during an oral glucid tolerance test

Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUIl/L) of Δpeak (difference from the baseline at Cmax), between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120

Time frame: 26 weeks